194 related articles for article (PubMed ID: 23884447)
21. Axillary lymph node dissection in pT1 breast cancer: a retrospective analysis of 315 patients and review of the literature.
Witt A; Obwegeser R; Auerbach L; Tempfer C; Yavuz D; Kubista E
Wien Klin Wochenschr; 2002 Jun; 114(10-11):387-90. PubMed ID: 12708092
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
[TBL] [Abstract][Full Text] [Related]
23. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Wang LL; Hao S; Zhang S; Guo LJ; Hu CY; Zhang G; Gao B; Zhao JJ; Jiang Y; Tian WG; Wang J; Luo DL
Hum Pathol; 2017 Mar; 61():49-57. PubMed ID: 27864123
[TBL] [Abstract][Full Text] [Related]
24. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
[TBL] [Abstract][Full Text] [Related]
25. Lymphatic mapping and sentinel lymphadenectomy in early stage breast carcinoma.
Altinyollar H; Kapucuoglu N; Pak I; Berberoglu U
J Exp Clin Cancer Res; 2000 Jun; 19(2):141-4. PubMed ID: 10965808
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
27. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
28. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
29. The presentation of contralateral axillary lymph node metastases from breast carcinoma: a clinical management dilemma.
Huston TL; Pressman PI; Moore A; Vahdat L; Hoda SA; Kato M; Weinstein D; Tousimis E
Breast J; 2007; 13(2):158-64. PubMed ID: 17319857
[TBL] [Abstract][Full Text] [Related]
30. [Axillary lymph node metastases in breast cancer. Anatomo-clinical correlation and surgical approach].
Coroş MF; Stolnicu S; Georgescu R; Roşca A; Sorlea S; Dobre A; Podeanu D; Pălăsan A; Man C; Turcan C
Chirurgia (Bucur); 2009; 104(5):557-64. PubMed ID: 19943554
[TBL] [Abstract][Full Text] [Related]
31. Predicting axillary sentinel node status in patients with primary breast cancer.
Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H
Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
[TBL] [Abstract][Full Text] [Related]
33. Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study.
Wang C; Iakovlev VV; Wong V; Leung S; Warren K; Iakovleva G; Arneson NC; Pintilie M; Miller N; Youngson B; McCready DR; Done SJ
Genes Chromosomes Cancer; 2009 Dec; 48(12):1091-101. PubMed ID: 19760610
[TBL] [Abstract][Full Text] [Related]
34. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Troxell ML; Levine J; Beadling C; Warrick A; Dunlap J; Presnell A; Patterson J; Shukla A; Olson NR; Heinrich MC; Corless CL
Mod Pathol; 2010 Jan; 23(1):27-37. PubMed ID: 19898424
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
36. CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast.
Looi LM; Cheah PL; Zhao W; Ng MH; Yip CH
Malays J Pathol; 2006 Dec; 28(2):83-6. PubMed ID: 18376796
[TBL] [Abstract][Full Text] [Related]
37. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
[TBL] [Abstract][Full Text] [Related]
38. Predictors of nonsentinel node metastasis in patients with breast cancer after sentinel node metastasis.
Joseph KA; El-Tamer M; Komenaka I; Troxel A; Ditkoff BA; Schnabel F
Arch Surg; 2004 Jun; 139(6):648-51. PubMed ID: 15197092
[TBL] [Abstract][Full Text] [Related]
39. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
[TBL] [Abstract][Full Text] [Related]
40. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) and MUC1 from the axillary fluid drainage in patients after breast cancer surgery.
Greenberg R; Barnea Y; Schneebaum S; Kashtan H; Kaplan O; Skornik Y
Isr Med Assoc J; 2003 Sep; 5(9):649-52. PubMed ID: 14509156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
